Clinical Study on the Second-line Treatment of Advanced non-small Cell Lung Cancer with Androtinib and Docetaxel
Objective To investigate the clinical efficacy and safety of erlotinib combined with docetaxel in the treatment of advanced non-small cell lung cancer(NSCLC).Methods 84 patients with advanced NSCLC were selected and divided into 2 groups according to the random number table,42 patients in each group.The control group was treated with docetaxel,and the ob-servation group was treated with arrotinib for 2 cycles.The clinical efficacy,tumor marker level,quality of life and adverse reac-tions of the 2 groups were compared.Results The disease control rate of the observation group was higher than that of the control group(P＜0.05);Carcinoembryonic antigen(CEA)after treatment in the observation group[(7.15±1.03)]μg/L],vascular endothelial growth factor(VEGF)[(55.36±5.18)ng/L],carbohydrate antigen 50(CA50)[(10.29±1.29)U/ml]and cytok-eratin 19 fragment antigen 21-1(CYFRA21-1)levels[(2.04±0.42)ng/ml]were lower than those in the control group[(9.28±1.24)μg/L,(64.15±6.27)ng/L,(12.02±2.05)U/ml,(2.58±0.44)ng/ml],with statistical difference(P＜0.05);After treatment,the scores of physiological field[(84.76±7.29)points],psychological field[(82.58±7.14)points],environmental field[(88.31±8.25)points]and social field[(86.65±7.29)points]in the observation group were higher than those in the control group[(75.85±7.15)points,(73.35±6.89)points,(81.64±8.15)points,(80.75±7.05)points],with statistical differences(P＜0.05);There were no serious adverse reactions in both groups.Conclusion Androtinib combined with docetaxel can enhance the control effect of advanced NSCLC,reduce the levels of CEA,VEGF,CA50,CYFRA21-1,improve the quality of life,and do not increase the risk of adverse reactions.
Non-small cell lung cancerAndrotinibDocetaxelClinical efficacyTumor markersQuality of life
NETL
NSTL
万方数据
